Clazakizumab for the treatment of chronic active antibody-mediated rejection (AMR) in kidney transplant recipients: Phase 3 IMAGINE study rationale and design

Abstract Background Chronic active antibody-mediated rejection (AMR) is a major cause of graft loss with no approved drugs for its treatment. Currently, off-label regimens are used, reflecting the high unmet need for effective therapies based on well-controlled trials. Clazakizumab is a high-affinit...

पूर्ण विवरण

ग्रंथसूची विवरण

मुख्य लेखकों:	Peter W. Nickerson, Georg A. Böhmig, Steve Chadban, Deepali Kumar, Roslyn B. Mannon, Teun van Gelder, James C. Lee, Scott Adler, Edward Chong, Arjang Djamali
स्वरूप:	Artigo
भाषा:	Inglês
प्रकाशित:	BMC 2022-12-01
श्रृंखला:	Trials
विषय:	Chronic active antibody-mediated rejection Clazakizumab Estimated glomerular filtration rate Kidney transplantation
ऑनलाइन पहुंच:	https://doi.org/10.1186/s13063-022-06897-3
टैग:	टैग जोड़ें कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!